Uscom Limited (UCM) AI Stock Analysis

• Market Cap: AU$3.64M
• Dividend Yield: N/A
• Average Volume (3M): 147.84K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.57
• Revenue Growth: 2.91%
• EPS Growth: 13.51%
• Country: AU
• Employees: 35
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 260,147,130
• 10 Day Avg. Volume: 88,663
• 30 Day Avg. Volume: 147,842
• PEG Ratio: 0.05
• Price to Book (P/B): 1.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.40
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: AU$0.00 ▼(-100.00%Downside)

The stock score is primarily driven by financial instability due to ongoing profitability challenges and negative cash flow metrics. Technical analysis further compounds the negative outlook with bearish trends. Valuation concerns with a negative P/E ratio and lack of dividend yield also weigh down the score.

Uscom Limited Business Overview & Revenue Model

Company Description

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company also provides the SpiroSonic AIR, a digital multipath ultrasonic spirometer with a viral disinfection system for the elimination of COVID and tuberculosis; and respiratory devices. It serves hospitals and other medical care locations through a network of distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.

How the Company Makes Money

Uscom Limited generates revenue primarily through the sale of its medical devices to hospitals, clinics, and healthcare professionals. The company's key revenue streams include direct sales of its hemodynamic monitoring systems and spirometers, as well as ongoing service and maintenance contracts. Additionally, Uscom may engage in partnerships or collaborations with healthcare institutions and research organizations, contributing to its earnings through joint ventures and co-development agreements.

Uscom Limited Financial Statement Overview

Summary

Uscom Limited shows revenue growth but struggles with consistent profitability, negative EBIT, and net income. The balance sheet indicates manageable leverage but declining equity ratios and negative cash flow metrics suggest financial instability.

Income Statement

Uscom Limited shows a fluctuation in its revenue, with a notable increase in the recent year. However, the company has consistently reported negative EBIT and net income, indicating ongoing profitability challenges. While the gross profit has improved, the net profit margin remains negative, which is a significant concern.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio, suggesting manageable leverage levels. However, the equity ratio has been declining, indicating potential risks in asset management. The return on equity has been negative, highlighting the company's struggle to generate profit from its equity base.

Cash Flow

Cash flow analysis reveals persistent negative free cash flow, though operating cash flow has shown some improvement in recent periods. The free cash flow to net income ratio remains unfavorable, suggesting that the company is facing challenges in converting profits into cash.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	3.63M	3.73M	2.66M	2.51M	3.86M	3.48M
Gross Profit	3.04M	3.12M	-1.03M	-1.21M	781.70K	458.00K
EBITDA	-2.09M	-1.51M	-2.53M	-1.84M	-833.84K	-672.88K
Net Income	-2.36M	-2.07M	-2.59M	-1.97M	-924.24K	-1.33M
Balance Sheet
Total Assets	4.64M	5.13M	5.18M	7.99M	5.33M	5.92M
Cash, Cash Equivalents and Short-Term Investments	2.16M	2.52M	2.18M	4.70M	1.71M	1.92M
Total Debt	1.86M	989.28K	1.09M	1.31M	1.43M	1.62M
Total Liabilities	2.76M	2.07M	2.14M	2.06M	2.26M	2.50M
Stockholders Equity	1.88M	3.06M	3.04M	5.94M	3.08M	3.42M
Cash Flow
Free Cash Flow	-1.52M	-1.22M	-1.58M	-1.08M	21.63K	-321.38K
Operating Cash Flow	-1.51M	-1.16M	-1.42M	-967.51K	54.98K	-283.23K
Investing Cash Flow	-56.85K	-57.55K	-151.94K	-115.31K	-33.35K	-38.16K
Financing Cash Flow	536.63K	1.57M	-952.96K	4.05M	-281.87K	1.03M

Uscom Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:UCM, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 9.09 is Positive, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:UCM.

Uscom Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	46 Neutral	C$202.00M	-3.18	-23.14%	2.74%	21.17%	-0.61%
UCM	45 Neutral	AU$3.64M	―	-117.20%	―	2.91%	13.51%
1I4	―	€5.90M	―	-321.94%	―	―	―
ADR	47 Neutral	AU$10.78M	―	-375.15%	―	-59.01%	17.13%
CBL	42 Neutral	AU$11.20M	―	-98.08%	―	-7.44%	30.34%
AT1	39 Underperform	AU$11.56M	―	-61.15%	―	35.63%	18.55%
IRX	38 Underperform	AU$8.96M	―	-191.40%	―	―	19.74%

Uscom Limited Corporate Events

Uscom Limited Secures A$2 Million in Short-Term Loans for Working Capital

Uscom Limited has secured two short-term loans totaling A$2,000,000 to bolster its working capital. The loans, one from Executive Chairman Assoc. Prof Robert Phillips and another from Jetan Pty Limited, each carry a 15% interest rate and are unsecured, with repayment due by June 30, 2026. This financial maneuver is expected to support Uscom’s operational liquidity and potentially strengthen its market position.

Uscom Limited Director Increases Shareholding Through Performance Rights Conversion

Uscom Limited announced a change in the director’s interest, with Robert Allan Phillips converting 9,670,117 performance rights into ordinary shares, increasing his total holdings to 93,958,881 shares. This conversion, approved at the 2024 AGM, reflects a strategic move to align the director’s interests with the company’s growth, potentially impacting stakeholder confidence and market perception positively.

Uscom Limited Issues New Shares to Bolster Growth

Uscom Limited has issued 9,670,117 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, in compliance with relevant legal provisions. This strategic move could potentially enhance the company’s financial standing and operational capacity, reflecting its commitment to growth and adherence to regulatory standards.

Uscom Limited Issues New Securities to Strengthen Market Position

Uscom Limited has announced the issuance of 9,670,117 new ordinary fully paid securities, which will be quoted on the ASX starting July 7, 2025. This move is part of the company’s strategy to enhance its capital structure, potentially impacting its market position and providing opportunities for growth and expansion in the medical technology sector.

Uscom Limited Reports Increased Revenue Amid Global Challenges

Uscom Limited released its quarterly cash report for the period ending March 31, 2025, showing a 14% increase in customer receipts compared to the previous quarter, despite a challenging global trade environment. The company’s operational highlights include significant clinical achievements, strengthened partnerships with Foxconn and SinoPharm, and the establishment of a new subsidiary in China to support expansion. With new products and strategic partnerships, Uscom is well-positioned for growth in anticipation of a more stable global economic environment.